Cardiovascular Therapeutics: A Companion to Braunwald's Heart DiseaseThis companion to Braunwald's Heart Disease equips you with all of today's most effective therapeutic guidelines and management solutions for the full range of heart disease patients. It reflects the most recent standards for drug management as well as the latest in new technologies. Reorganized to mirror your changing practice, each cardiovascular-problem-based section offers a chapter on pharmacologic treatment (with a minimum of pathophysiology)...a chapter on catheter-based or minimally invasive interventions...and a discussion of surgical options. You'll also find a brand-new chapter on gene therapy and stem cell therapy, plus new chapters on many other rapidly developing areas of practice. The result is an outstanding single-volume source for state-of-the-art, clinically oriented guidance on both common and unusual areas of cardiovascular treatment.
|
What people are saying - Write a review
We haven't found any reviews in the usual places.
Contents
Current Approaches to Revascularization | 157 |
LongTerm Secondary Prevention | 172 |
Primary Prevention of Ischemic Heart | 178 |
Copyright | |
20 other sections not shown
Other editions - View all
Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease Elliott M. Antman Limited preview - 2007 |
Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease Elliott M. Antman Limited preview - 2007 |
Common terms and phrases
ablation activity acute myocardial infarction addition agents analysis angina angioplasty arrhythmias artery disease aspirin assessment associated B-blockers benefit blood pressure bypass CABG cardiac Cardiol cardiovascular cause cells cholesterol chronic Circulation clinical clinical trials Coll Cardiol combination compared complications congestive coronary artery cost death decreased demonstrated device diabetes dose drug dysfunction early effects Engl et al Evaluation exercise factors Figure flecainide function gene glucose graft guidelines half-life heart disease heart failure hospital hypertension implantation important improved increased indicated inhibition inhibitors initial intervention ischemic left ventricular lesions less levels long-term lower major mechanisms mortality nitrate outcomes patients percutaneous prevention primary procedure pulmonary ramipril randomized receptor recommended reduced renal reported restenosis revascularization risk severe significant stent strategy surgery symptoms syndrome Table therapy tion transplantation treated treatment trial vascular versus